NASDAQ:CBLI - Cleveland BioLabs Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.60 -0.01 (-0.62 %) (As of 05/19/2019 12:32 PM ET)Previous Close$1.60Today's Range$1.50 - $1.6052-Week Range$1.00 - $3.16Volume1,634 shsAverage Volume55,055 shsMarket Capitalization$18.08 millionP/E RatioN/ADividend YieldN/ABeta0.75 ProfileChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York. Receive CBLI News and Ratings via Email Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBLI Previous Symbol CUSIPN/A CIK1318641 Webwww.cbiolabs.com Phone716-849-6810Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio4.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.14 million Price / Sales15.86 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book6.67Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,610,000.00 Net Margins-293.37% Return on Equity-84.17% Return on Assets-62.83%Miscellaneous EmployeesN/A Outstanding Shares11,300,000Market Cap$18.08 million Next Earnings Date5/21/2019 (Estimated) OptionableNot Optionable Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions What is Cleveland BioLabs' stock symbol? Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI." How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter. The biotechnology company earned $0.28 million during the quarter. Cleveland BioLabs had a negative return on equity of 84.17% and a negative net margin of 293.37%. View Cleveland BioLabs' Earnings History. When is Cleveland BioLabs' next earnings date? Cleveland BioLabs is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Cleveland BioLabs. Has Cleveland BioLabs been receiving favorable news coverage? Headlines about CBLI stock have been trending positive on Sunday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cleveland BioLabs earned a coverage optimism score of 2.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Cleveland BioLabs' key competitors? Some companies that are related to Cleveland BioLabs include Senomyx (SNMX), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Bioanalytical Systems (BASI), Vitality Biopharma (VBIO), Tenax Therapeutics (TENX), US Stem Cell (USRM), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY), National Research (NRCIA), National Research (NRCIB), Redpoint Bio (RPBC) and VIRALYTICS Ltd/S (VRACY). What other stocks do shareholders of Cleveland BioLabs own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include Nektar Therapeutics (NKTR), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and Rigel Pharmaceuticals (RIGL). Who are Cleveland BioLabs' key executives? Cleveland BioLabs' management team includes the folowing people: Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory AffairsDr. Andrei Purmal Ph.D., VP of Chemistry Who are Cleveland BioLabs' major shareholders? Cleveland BioLabs' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.60%). View Institutional Ownership Trends for Cleveland BioLabs. Which major investors are buying Cleveland BioLabs stock? CBLI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Cleveland BioLabs. How do I buy shares of Cleveland BioLabs? Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cleveland BioLabs' stock price today? One share of CBLI stock can currently be purchased for approximately $1.60. How big of a company is Cleveland BioLabs? Cleveland BioLabs has a market capitalization of $18.08 million and generates $1.14 million in revenue each year. What is Cleveland BioLabs' official website? The official website for Cleveland BioLabs is http://www.cbiolabs.com. How can I contact Cleveland BioLabs? Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected] MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 121 (Vote Outperform)Underperform Votes: 101 (Vote Underperform)Total Votes: 222MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: S&P 500 Index Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.